Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Target Price
The average target price of LUCD is 4.2 and suggests 194% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell